Dr. Giselle S. Mosnaim, MD

Dr. Mosnaim practices at Northshore University Healthsystem - Evanston Hospital - Glenview HOPD (2050 Pfingsten) in Glenview, Illinois.

Dr. Mosnaim's NPI, 1679501571, was assigned on June 29, 2006. Dr. Mosnaim holds Illinois license 036-095785.

Dr. Mosnaim's primary practice is Northshore University Healthsystem - Evanston Hospital - Glenview HOPD (2050 Pfingsten), at 2050 Pfingsten, Glenview, IL 60026.

Dr. Mosnaim's primary practice is Northshore University Healthsystem - Evanston Hospital - Glenview HOPD (2050 Pfingsten) in Glenview, Illinois. Dr. Mosnaim is also affiliated with Evanston Hospital. The medical group on file is Endeavor Health Medical Group. Dmand AI also links Dr. Mosnaim to 1 more hospital and 1 group practice or clinic, each named with a free account. Dr. Mosnaim's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mosnaim practices, 4 sites in all. Vendor and product names are available with a free account.

Allergy and immunology is Dr. Mosnaim's primary specialty in the NPI Registry, under taxonomy code 207K00000X. Dr. Mosnaim is licensed in Illinois.

CMS data shows 166 Medicare services from Dr. Mosnaim across 3 procedure codes in 2024, for 98 Medicare patients. Medicare paid $11,032 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 98 Medicare patients who saw Dr. Mosnaim in 2024. The largest group is 65 to 74, with 54 patients. 75% of them have high cholesterol, and 53% have arthritis. 11% are also on Medicaid. Their average risk score is 1.04, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Mosnaim's median patient age at 47, with 62% women.

In 2024, Dr. Mosnaim wrote 669 Medicare Part D claims for 126 patients. 63% of them were for generic drugs. CMS names the drug for 565 of them, across 16 drugs with 11 or more claims each, at $783,555 in total drug cost. In 2023, CMS named 590 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Mosnaim for performance year 2024, reported as part of a group. Dr. Mosnaim accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 85 papers to Dr. Mosnaim, published from 2011 to 2025. 2020 was the busiest year, with 14. The most frequent topics are Asthma, Administration, Inhalation and Anti-Asthmatic Agents. Dr. Mosnaim has published most often in J Allergy Clin Immunol Pract. Dr. Mosnaim's most frequent co-authors are John J. Oppenheimer, MD, Matthew Jason Greenhawt, MBA, MD and Valerie G. Press.

Dmand AI links Dr. Mosnaim to 7 clinical trials, 3 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Asthma, Respiratory Hypersensitivity and COVID-19. Johns Hopkins University sponsors the most, 2. Open Payments lists research payments to Dr. Mosnaim that name 4 trials.

CMS Open Payments shows 420 general payments to Dr. Mosnaim from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 49% of the total. Novartis Pharmaceuticals Corporation paid the most, $78,651. It also lists 109 research payments totaling $81,612 from 2017 to 2025, naming 4 clinical trials.